Connect with us

Hi, what are you looking for?

Top Stories

Moderna’s mRNA Flu Vaccine Surpasses Standard in Phase III Trials

Moderna is poised to seek regulatory approval for its mRNA flu vaccine following a successful Phase III trial. The vaccine, known as mRNA-1010, demonstrated superior efficacy compared to the current standard flu vaccine, marking a significant advancement in influenza prevention.

The study, which enrolled 40,805 participants across 11 countries, focused on adults aged 50 and older. It assessed the relative vaccine efficacy (rVE) of mRNA-1010 against a licensed standard-dose seasonal influenza vaccine. The results revealed an rVE of 26.6%, indicating a notable improvement over existing options.

Detailed Findings and Implications

The pivotal trial (NCT06602024) highlighted the vaccine’s effectiveness against multiple flu strains. Each strain within the vaccine, including A/H1N1, A/H3N2, and the B/Victoria lineages, showed robust efficacy with rVEs of 29.6%, 22.2%, and 29.1% respectively. These findings were consistent across various subgroups, regardless of age, risk factors, or previous influenza vaccination status.

“The severity of this past flu season underscores the need for more effective vaccines. An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for Covid-19 combination vaccines.” — Stéphane Bancel, Moderna CEO

Moderna’s mRNA-1010 also demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all included strains in a previous Phase III trial. This was in comparison to both high-dose and standard-dose licensed seasonal influenza vaccines.

Safety and Regulatory Pathway

The safety profile of mRNA-1010 was consistent with earlier studies, with most adverse events being mild. Injection site pain was the most commonly reported side effect. With these promising results, Moderna plans to engage with regulatory bodies to file submissions for mRNA-1010 approval.

This development comes at a turbulent time in the vaccine sector. Recently, US health secretary Robert F. Kennedy, Jr. made headlines by dismissing all members of the Advisory Committee on Immunization Practices (ACIP), replacing them with individuals known for their vaccine skepticism and criticism of Covid-19 vaccines and related public health measures.

Broader Context and Future Prospects

The ACIP plays a crucial role in advising the US Centers for Disease Control and Prevention on vaccination schedules. The current upheaval in this committee could have significant implications for vaccine policy and public health strategy in the United States.

Moderna’s advancement in mRNA technology not only represents a leap forward in flu prevention but also opens the door for future innovations, such as combination vaccines that could simultaneously protect against influenza and Covid-19. This potential for rapid adaptation to circulating strains could transform how flu vaccines are developed and deployed in the future.

As Moderna prepares to submit its findings to regulatory authorities, the healthcare community watches closely. The approval of mRNA-1010 could set a new standard in flu vaccination and bolster preparedness for future pandemics.

Stay informed with our daily news round-up and gain an edge with our industry insights. Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards, celebrating innovation, leadership, and impact in the field. Submit your nomination today to gain global recognition.

You May Also Like

Top Stories

California has taken a stand against a federal directive from the Trump administration demanding the exclusion of transgender athletes from girls’ and women’s sports....

Entertainment

Olivia Munn, the acclaimed actress, recently shared an intimate revelation about her personal struggles with trichotillomania, a disorder that compels individuals to pull out...

Top Stories

Frontier, a coalition of technology leaders including Google and Meta, has announced a landmark investment in Arbor, a cutting-edge startup specializing in bioenergy with...

Top Stories

URGENT UPDATE: Affordable motorcycle helmets under ₹1000 are now available for safety-conscious riders across India. With road safety becoming a pressing issue, these helmets...

Entertainment

Fans of My Chemical Romance were taken aback after revelations emerged about guitarist Frank Iero‘s past encounter with the FBI. The incident traces back...

Health

Ng Kuo Pin, CEO of NCS, announced a significant investment of S$130 million in artificial intelligence (AI) over the next three years. This initiative...

Science

New observations from the James Webb Space Telescope (JWST) are transforming our understanding of Europa, one of Jupiter’s moons. These findings reveal that the...

Politics

Lawmakers in Pennsylvania are exploring potential changes to the state’s sales tax exemptions as the General Assembly grapples with a significant budget deficit. This...

Business

Political commentator Brilyn Hollyhand has voiced strong opposition to the prospect of Elon Musk launching a third political party in 2025. In his commentary,...

Politics

President Donald Trump is closely monitoring Republican senators as they navigate a controversial rescissions package that demands significant cuts to foreign aid and public...

Entertainment

Bleacher Report’s recent release of its ranking of the Top 100 NBA players of all time has sparked significant backlash, particularly regarding the placement...

Top Stories

UPDATE: Meta Platforms just announced a staggering $14.8 billion investment in AI, ramping up its efforts to dominate the tech landscape. This move comes...

Copyright © All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site.